1. Home
  2. SCM vs ALLO Comparison

SCM vs ALLO Comparison

Compare SCM & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SCM
  • ALLO
  • Stock Information
  • Founded
  • SCM 2012
  • ALLO 2017
  • Country
  • SCM United States
  • ALLO United States
  • Employees
  • SCM N/A
  • ALLO N/A
  • Industry
  • SCM Finance/Investors Services
  • ALLO Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • SCM Finance
  • ALLO Health Care
  • Exchange
  • SCM Nasdaq
  • ALLO Nasdaq
  • Market Cap
  • SCM 392.6M
  • ALLO 427.7M
  • IPO Year
  • SCM 2012
  • ALLO 2018
  • Fundamental
  • Price
  • SCM $15.41
  • ALLO $2.17
  • Analyst Decision
  • SCM Hold
  • ALLO Strong Buy
  • Analyst Count
  • SCM 2
  • ALLO 10
  • Target Price
  • SCM $13.63
  • ALLO $10.06
  • AVG Volume (30 Days)
  • SCM 139.4K
  • ALLO 9.8M
  • Earning Date
  • SCM 03-03-2025
  • ALLO 03-13-2025
  • Dividend Yield
  • SCM 10.39%
  • ALLO N/A
  • EPS Growth
  • SCM 307.51
  • ALLO N/A
  • EPS
  • SCM 1.96
  • ALLO N/A
  • Revenue
  • SCM $107,143,385.00
  • ALLO $43,000.00
  • Revenue This Year
  • SCM $0.34
  • ALLO N/A
  • Revenue Next Year
  • SCM N/A
  • ALLO N/A
  • P/E Ratio
  • SCM $7.86
  • ALLO N/A
  • Revenue Growth
  • SCM 5.88
  • ALLO 26.47
  • 52 Week Low
  • SCM $12.63
  • ALLO $1.32
  • 52 Week High
  • SCM $15.55
  • ALLO $5.78
  • Technical
  • Relative Strength Index (RSI)
  • SCM 76.62
  • ALLO 55.14
  • Support Level
  • SCM $15.29
  • ALLO $1.32
  • Resistance Level
  • SCM $15.55
  • ALLO $3.78
  • Average True Range (ATR)
  • SCM 0.21
  • ALLO 0.36
  • MACD
  • SCM 0.04
  • ALLO 0.10
  • Stochastic Oscillator
  • SCM 87.72
  • ALLO 34.55

About SCM Stellus Capital Investment Corporation

Stellus Capital Investment Corp is a closed-end, non-diversified management investment company. Its objective is to maximize the total return to its stockholders in the form of current income and capital appreciation. It invests in private middle-market companies through a first lien, second lien, and unsecured debt financing, often with a corresponding equity investment. The company invests in various sectors, such as business services, energy, general industrial, government services, healthcare, software, and specialty finance. Business activity of the firm is functioned through the United States and it generates revenue in the form of interest income on debt investments and capital gains and distributions.

About ALLO Allogene Therapeutics Inc.

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, primarily generated from collaborations and licensing agreements, supports their research and development efforts.

Share on Social Networks: